Fludarabine phosphate may be useful in the treatment of graft-versus-host disease

详细信息    查看全文

• 作者：Sercan Aksoy ; Huseyin Abali ; Saadettin Kilickap ; Murat Dinç ; er ; Mustafa Erman
• 刊名：Medical Hypotheses
• 出版年：2005
• 出版时间：2005
• 年：2005
• 卷：64
• 期：6
• 页码：1150-1152
• 全文大小：65 K

文摘

The increasing number of allogeneic stem cell transplantations has made the management of graft-versus-host disease (GVHD) a continuing problem for transplantation professionals. GVHD is a complicated disease the treatment of which requires an equally multifaceted approach. Despite therapeutic efforts to decrease its distressing and potentially lethal clinical manifestations, treatment is still not optimal.

Fludarabine phosphate is a purine analogue, which is known to cause immunosuppression and long-lasting T-cell lymphopenia it is commonly employed in the therapy of hematological malignancies and non-myeloablative stem cell transplantation conditioning regimens. Myelosuppression, especially leuko- and lymphopenia is the major dose-limiting toxicity of fludarabine. However, a prolonged reduction in CD4+ T-cell count may be a desired effect for the treatment of GVHD.

Clinical observations, preclinical data on the management of GVHD and well-known immunosuppressive properties suggest that fludarabine should be tested in clinical grounds for GVHD prophylaxis and treatment.